Victrex (VCT) H2 2025 earnings summary

Executive summary

• FY 2025 saw 12% sales volume growth, mainly from value-added resellers and energy/industrial, with strong cash conversion and a 1% revenue increase, despite a challenging chemical industry environment.

• Underlying profit before tax fell 21% to £46.4m, impacted by currency, sales mix, and China start-up costs.

• A profit improvement plan targeting at least £10m in savings was announced, leveraging digital and infrastructure investments, with full-year benefits expected in FY27.

• Cash conversion remained strong at 121%, aided by working capital management and reduced CapEx.

• Updated capital allocation policy maintains dividends and targets net debt/EBITDA in the 0.5x–1.0x range.

Financial highlights

• Revenue increased 1% to £292.7m (3% in constant currency); gross profit down 1% to £132.6m, but up 5% in constant currency.

• Gross margin declined 90bps to 45.3% (47.7% ex-China plant impact).

• Underlying PBT down 21% to £46.4m (down 10% in constant currency); reported PBT up 44% to £33.8m due to lower exceptionals.

• Free cash flow was £49.3m; net debt increased to £24.8m (net debt/EBITDA 0.34x).

• Dividend per share maintained at 59.56p.

Outlook and guidance

• FY 2026 targets low to mid-single digit volume growth, stable ASP, and gross margin in the 45.5%–46.5% range.

• Profit improvement plan to deliver at least £10m savings, with most benefits in FY 2027 and exceptional costs of ~£10m.

• CapEx to remain disciplined, at or below 8–10% of revenues.

• Growth and profit expected to be second-half weighted due to seasonality and currency headwinds in H1.

• Medical spine remains weak; sustainable solutions and VAS expected to see similar mix as late FY 2025.